Sanguine's PHER-O2 Successfully Completes Animal Safety and Efficacy Trials at
                           the University of Alberta

PASADENA, Calif., Wednesday, November 17, 2004 /Business Wire/ -- Sanguine
Corporation (The Company) (OTC Bulletin Board: SGNC), a bio-pharmaceutical
company focused on the development of an oxygen-carrying synthetic substitute
for human red blood cells, announced its product, PHER-O2 has successfully
completed animal toxicity & efficacy trials at the University of Alberta in
Edmonton, Canada.  The Company expects to have additional information related
to human testing by the University in the next few weeks.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corporation, stated,
"Diabetes is the fastest growing chronic disease in the U.S. and the world.
Islet cells produce insulin, which diabetics lack.  We are excited to aid the
University of Alberta in their endeavors with a supply of PHER-O2."

Sanguine Corporation is a development-stage company focused on the research
and development of PHER-O2, a synthetic red blood cell product with potential
applications in a variety of specialties, including: transfusions, CAT scans,
cardioplegia and the treatment of heart attacks, strokes, head and neck tumors
and hemorrhagic shock. The Company is also developing non-medical applications
for its perfluorocarbon (PFC) product.

Contact: Investor Relations: Michael Dancy, 801-746-3570, email:
medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange Commission.